Paper40649226
Hybrid Molecules with Purine and Pyrimidine Derivatives for Antitumor Therapy: News, Perspectives, and Future Directions.
Iacob Ciobotaru S and 9 others. Molecules, 2025. Cited by 9 papers, by iCite.
Cite this record
ConductScience Library. Hybrid Molecules with Purine and Pyrimidine Derivatives for Antitumor Therapy: News, Perspectives, and Future Directions. Papers, record 40649226. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40649226
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Hybrid Molecules with Purine and Pyrimidine Derivatives for Antitumor Therapy: News, Perspectives, and Future Directions.
- PubMed
Topics6
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Pyrimidines | Major topic |
| Purines | Major topic |
| Antineoplastic Agents | Major topic |
| Neoplasms | Major topic |
| Humans | |
| Animals |
Source PubMed
Grants1
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 7969/31.03.2025 | "Dunărea de Jos University of Galați" | PubMed |
Source PubMed
References114
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 36707808 | Safety and efficacy of trifluridine/tipiracil in previously treated metastatic colorectal cancer: final results from the phase IIIb single-arm PRECONNECT study by duration of therapy. | BMC Cancer | 2023 | https://conductscience.org/library/papers/36707808 | PubMed |
| 2 | 30667505 | Breast Cancer Treatment: A Review. | JAMA | 2019 | https://conductscience.org/library/papers/30667505 | PubMed |
| 3 | 11888330 | Cellular and clinical pharmacology of fludarabine. | Clin Pharmacokinet | 2002 | https://conductscience.org/library/papers/11888330 | PubMed |
| 4 | 15763604 | Capecitabine: a review. | Clin Ther | 2005 | https://conductscience.org/library/papers/15763604 | PubMed |
| 5 | 23060388 | Molecular mechanism of acrylamide neurotoxicity: lessons learned from organic chemistry. | Environ Health Perspect | 2012 | https://conductscience.org/library/papers/23060388 | PubMed |
| 6 | 24190492 | Purvalanol A is a strong apoptotic inducer via activating polyamine catabolic pathway in MCF-7 estrogen receptor positive breast cancer cells. | Mol Biol Rep | 2014 | https://conductscience.org/library/papers/24190492 | PubMed |
| 7 | 29642417 | Molecular Consortia-Various Structural and Synthetic Concepts for More Effective Therapeutics Synthesis. | Int J Mol Sci | 2018 | https://conductscience.org/library/papers/29642417 | PubMed |
| 8 | 33305635 | Have molecular hybrids delivered effective anti-cancer treatments and what should future drug discovery focus on? | Expert Opin Drug Discov | 2021 | https://conductscience.org/library/papers/33305635 | PubMed |
| 9 | 17627520 | Molecular hybridization: a useful tool in the design of new drug prototypes. | Curr Med Chem | 2007 | https://conductscience.org/library/papers/17627520 | PubMed |
| 10 | 33387732 | Design, synthesis and in silico insights of new 7,8-disubstituted-1,3-dimethyl-1H-purine-2,6(3H,7H)-dione derivatives with potent anticancer and multi-kinase inhibitory activities. | Bioorg Chem | 2021 | https://conductscience.org/library/papers/33387732 | PubMed |
| 11 | 31566975 | Hydration of Aromatic Heterocycles as an Adversary of π-Stacking. | J Chem Inf Model | 2019 | https://conductscience.org/library/papers/31566975 | PubMed |
| 12 | 21242742 | Cladribine: mode of action and implications for treatment of multiple sclerosis. | Clin Neuropharmacol | 2011 | https://conductscience.org/library/papers/21242742 | PubMed |
| 13 | 11114313 | Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. | N Engl J Med | 2000 | https://conductscience.org/library/papers/11114313 | PubMed |
| 14 | 20722491 | Safety of capecitabine: a review. | Expert Opin Drug Saf | 2010 | https://conductscience.org/library/papers/20722491 | PubMed |
| 15 | 26081925 | Purine Analogues as Kinase Inhibitors: A Review. | Recent Pat Anticancer Drug Discov | 2015 | https://conductscience.org/library/papers/26081925 | PubMed |
| 16 | 35517208 | Synthesis and biological evaluation of dehydroabietic acid-pyrimidine hybrids as antitumor agents. | RSC Adv | 2020 | https://conductscience.org/library/papers/35517208 | PubMed |
| 17 | 4910304 | The crystal structures of purines, pyrimidines and their intermolecular complexes. | Prog Nucleic Acid Res Mol Biol | 1970 | https://conductscience.org/library/papers/4910304 | PubMed |
| 18 | 40006082 | Design, Synthesis, and Mechanistic Anticancer Evaluation of New Pyrimidine-Tethered Compounds. | Pharmaceuticals (Basel) | 2025 | https://conductscience.org/library/papers/40006082 | PubMed |
| 19 | 32918216 | Epidemiology of Skin Cancer: Update 2019. | Adv Exp Med Biol | 2020 | https://conductscience.org/library/papers/32918216 | PubMed |
| 20 | 25084222 | Gemcitabine: metabolism and molecular mechanisms of action, sensitivity and chemoresistance in pancreatic cancer. | Eur J Pharmacol | 2014 | https://conductscience.org/library/papers/25084222 | PubMed |
Cited by6
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 9 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42513119 | Selected Thieno[2,3-d] Pyrimidine Derivatives Target Breast Cancer Cell Proliferation and Membrane Organization. | Molecules | 2026 | https://conductscience.org/library/papers/42513119 | PubMed |
| 42495331 | Recent Advances in Pyrimidine Molecular Hybrids, Green Synthetic Strategies, and Diverse Biological Applications. | ACS Omega | 2026 | https://conductscience.org/library/papers/42495331 | PubMed |
| 42105200 | Designing the Next Generation of Antibiotics: Structure, SAR, and Strategy in Medicinal Chemistry (2000-2025). | Med Res Rev | 2026 | https://conductscience.org/library/papers/42105200 | PubMed |
| 41602180 | Thienopyrimidine scaffolds as promising antimicrobial agents: synthesis, biological evaluation, DFT analysis and molecular docking. | RSC Adv | 2026 | https://conductscience.org/library/papers/41602180 | PubMed |
| 41266472 | Design, synthesis, and biological evaluation of novel 6-(4-aminopiperidin-1-yl)-substituted benzyl-3-methylpyrimidine-2,4(1H,3H)-dione derivatives as potential anticancer agents targeting thymidylate synthase. | Sci Rep | 2025 | https://conductscience.org/library/papers/41266472 | PubMed |
| 41183108 | Novel pyrimidine-substituted chalcones: In vitro antioxidant properties and cytotoxic effects against human cancer cell lines. | PLoS One | 2025 | https://conductscience.org/library/papers/41183108 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40649226
GET https://conductscience.org/api/papers/v1/40649226/references?page=2